Zepbound

Eli Lilly reported higher-than-expected earnings as revenue from its weight loss drugs Mounjaro and Zepbound surged, with Mounjaro revenue rising 91% to $9.9 billion and Zepbound generating $4.9 billion.

Lilly's revenue increased by 48% due to strong demand for its GLP-1 drugs Mounjaro and Zepbound, which are used for treating Type 2 diabetes and weight loss.

Eli Lilly reported quarterly results that exceeded expectations, leading to an upward revision of its 2026 revenue forecast. The company now anticipates revenue between $85 billion and $87 billion for 2026, driven by strong sales of Zepbound and Mounjaro.

CVS exceeded estimates and raised guidance due to improvements in its insurance unit. The company announced a collaboration with Eli Lilly to make Zepbound and Foundayo accessible to eligible patients via the CVS Health app.

Walmart, Costco, and Amazon are competing to provide direct-to-consumer access to weight loss drugs like Wegovy and Zepbound as employers reduce coverage for these medications.

Patients taking GLP-1 medications like Ozempic, Wegovy, or Zepbound may need extended fasting or adjusted care before surgery due to slowed stomach emptying, which increases aspiration risk under anesthesia. Physician anesthesiologists require detailed medication information to ensure safe procedures, though most patients undergo surgery without complications.

A growing trend of microdosing GLP-1 drugs like Ozempic and Wegovy is spreading via social media, with users altering doses to reduce costs and side effects. However, this practice lacks FDA approval and clinical testing, posing unpredictable health risks. Pharmacist Sue Ojageer warns that self-directed microdosing bypasses medical supervision and may not be safer than standard prescriptions.

Novo Nordisk is requesting a court to block Eli Lilly's advertisements for Zepbound and Mounjaro, alleging the ads use outdated data and fail to mention newer, higher-dose versions of Wegovy and Ozempic.

Mosaic Fertilizer and Tampa Port Services agreed to a $103,000 federal penalty for an ammonia release incident. Eli Lilly's experimental obesity drug retatrutide showed no increased heart risk in a safety study. U.S. jobless claims fell to 187,000, the lowest since 1969.

Eli Lilly's obesity drug retatrutide showed significant weight loss in a Phase 3 study but did not reduce cardiovascular risk. The U.S. Medicare program is offering injectable GLP-1 obesity medications like Wegovy, Foundayo, and Zepbound through a trial program for $50 monthly, with high patient demand for injectables despite expectations of pill preference.

A ReturnPro survey indicates GLP-1 medications like Ozempic and Wegovy are altering clothing shopping habits in the U.S., with 71% of users buying more apparel due to changing sizes and 65% purchasing multiple sizes for returns. Men were nearly twice as likely as women to buy multiple sizes for returns, while psychological factors linked to the drugs may drive spending shifts toward clothing and wellness.

A federal CMS pilot program offers limited coverage of three GLP-1 weight-management medications for qualifying Metro Nashville retirees on Medicare or Medicare Advantage. The program, separate from Metro’s health plan, requires a $50 monthly copay and mandates prescriptions be processed through a CMS system, not Metro’s plan. Vanderbilt University is studying the drugs’ potential for asthma and obesity.

Novo Nordisk sued Eli Lilly, alleging deceptive advertising claims about its weight-loss drug Zepbound compared to Novo Nordisk's Wegovy. The lawsuit claims Eli Lilly's ads use outdated clinical trials comparing different doses and mislead consumers into believing Zepbound is superior. Eli Lilly has defended its advertising and intends to contest the lawsuit.

Novo Nordisk sued Eli Lilly over claims that its weight-loss medications work better than Novo's, alleging deceptive advertising with outdated trials. The lawsuit, filed in New Jersey, accuses Lilly of comparing high doses of Zepbound to lower doses of Wegovy and Ozempic. Novo seeks a court order to stop the ads and a correction campaign, with a potential preliminary injunction if compliance is not voluntary.

Novo Nordisk is suing Eli Lilly over 'false and materially misleading' advertisements for its weight-loss and anti-diabetes treatments. The Danish pharmaceutical company alleges Eli Lilly is using outdated trial data to compare its highest doses against lower doses of Novo Nordisk's medicines.

Novo Nordisk is suing Eli Lilly, alleging that its TV and social media advertisements use outdated trial data to mislead consumers about the efficacy of weight loss drugs Zepbound and Mounjaro compared to rival injections.

Novo Nordisk sued Eli Lilly for allegedly running a deceptive ad campaign using outdated clinical trials to compare higher doses of its drugs Zepbound and Mounjaro with lower doses of Novo's Wegovy and Ozempic. The lawsuit, filed in New Jersey federal court, accuses Lilly of intentionally confusing consumers through misleading advertising.

Biogen's experimental Alzheimer's drug diranersen showed slowed cognitive decline in a mid-stage trial, prompting a potential Phase 3 trial. A study highlighted potential frailty risks in older adults using Eli Lilly's Zepbound and Novo Nordisk's Wegovy, urging closer monitoring for seniors.

The success of weight loss drugs, particularly Zepbound, has generated a $1.3 billion increase in donations to Christian ministries in the U.S. and Canada. This surge in giving is attributed to the growing popularity of these medications.

UVM Health plans to stop covering weight loss medications for employees starting September 2023, aiming to save $19 million annually. The decision affects GLP-1 drugs like Ozempic and Zepbound, which are costly out-of-pocket for employees, while coverage for diabetes treatment remains. Employees express concern over financial burden and health impacts.

A U.S. judge blocked Colorado from capping the price of Amgen's Enbrel, citing potential harm to the company, while a new Medicare program will offer obesity drugs at $50/month. Novo Nordisk and Eli Lilly's weight-loss treatments will be included in the trial.

Medicare will start covering weight-loss drugs via a temporary pilot program on July 1, allowing millions of enrollees access to medications like Wegovy and Zepbound at significantly reduced costs under a deal with Eli Lilly and Novo Nordisk. The program aims to address obesity as a treatable disease, offering seniors like Mary and Jeff Abrahamson affordable options that improve health outcomes.

A Medicare pilot program expands access to GLP-1 weight-loss medications like Wegovy and Zepbound for some seniors, offering subsidies as high as $50 per month. The program, running through 2027, requires a BMI above 35 or specific weight-related conditions for eligibility, though 6 million Medicare Part D recipients who might otherwise qualify will remain excluded. Concerns persist about potential bone and muscle density loss from rapid weight loss, but medical professionals suggest exercise can mitigate risks.

Medicare is offering select GLP-1 weight loss drugs for $50/month through a temporary trial until 2027, with eligibility based on BMI and specific health conditions. Covered medications include Eli Lilly's Foundayo and Zepbound, and Novo Nordisk's Wegovy, but exclusions apply for those with diabetes or sleep apnea.

Medicare will cover GLP-1 weight-loss treatments through a temporary pilot program starting July 1, allowing eligible participants to pay a $50 monthly co-pay. The program includes Eli Lilly’s Zepbound and Foundayo and Novo Nordisk’s Wegovy, with coverage ending by 2027 due to federal law restrictions. Eligibility requires a BMI of 35 or higher (or 30 with specific health conditions), and prior authorization is needed.

Experts in Charlotte, N.C., are raising concerns about the disposal of GLP-1 injection pens as the use of weight-loss drugs like Ozempic, Wegovy, and Zepbound surges. Studies estimate roughly 12% of U.S. adults are using these medications, prompting questions about post-use waste management.

Medicare will cover weight-loss drugs for the first time starting July 1 through a temporary pilot program called Medicare GLP-1 Bridge. The program aims to reduce costs for medications like Zepbound and Wegovy, which are expensive without insurance, providing financial relief for seniors like Mary and Jeff Abrahamson who previously relied on compounded versions of tirzepatide.

2-year results from the SUPPRESS-EARLY trial indicate that early use of tirzepatide (Mounjaro, Zepbound) in type 2 diabetes management significantly improves outcomes. The findings were presented at the American Diabetes Association annual meeting.

Insurance coverage for GLP-1 weight loss drugs like Zepbound and Wegovy is being dropped by many plans due to high costs, leaving patients to seek alternatives. Patients may retain coverage if the drugs are prescribed for related conditions like sleep apnea or diabetes through prior authorization.

Insurance companies are increasingly dropping coverage for weight loss drugs like Wegovy and Zepbound due to rising costs, pushing patients to purchase through telehealth providers or manufacturers. Hims partners with Wegovy to offer the drug directly, while CVS expands coverage for Eli Lilly's anti-obesity pill and reinstates Zepbound later this year.

A new meta-study compared three GLP-1 medications: tirzepatide (Zepbound, Mounjaro), semaglutide (Wegovy, Ozempic), and liraglutide (Saxenda, Victoza). The study evaluated their effectiveness in a head-to-head analysis.

A new meta-study compared three GLP-1 medications: tirzepatide (Zepbound, Mounjaro), semaglutide (Wegovy, Ozempic), and liraglutide (Saxenda, Victoza).

A new meta-study compared three GLP-1 medications: tirzepatide (Zepbound, Mounjaro), semaglutide (Wegovy, Ozempic), and liraglutide (Saxenda, Victoza) to determine their effectiveness.

GLP-1 weight loss drugs like Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound are popular, prompting competitors like Pfizer and Amgen to develop similar products. The article discusses market competition and strategies by Novo Nordisk and Eli Lilly to maintain dominance in the weight loss drug sector.

People taking GLP-1 weight-loss drugs like Ozempic, Wegovy, Mounjaro, and Zepbound may experience reduced physical activity despite weight loss, according to Fitbit data analysis. Researchers noted declines in daily steps and exercise levels, raising concerns about muscle mass loss and long-term health impacts.

Some employers plan to drop coverage of GLP-1 weight loss drugs in 2027 as usage rises, despite lower prices for medications like Novo Nordisk’s Zepbound and Eli Lilly’s Foundayo. Rapid adoption of GLP-1 drugs in the U.K. has reduced annual grocery spending by $1 billion, with 6.3% of households now including at least one user.

A study presented at the American Society of Clinical Oncology conference suggests GLP-1 weight-loss drugs like Wegovy and Zepbound may reduce breast cancer risk by over 30% in women. The observational study analyzed health records of 111,000 women and found those prescribed GLP-1 medications had significantly lower breast cancer incidence, though researchers caution the findings do not prove causation.

California's Senate passed a bill requiring health insurers to cover GLP-1 weight-loss drugs like Ozempic for public employees, but CalPERS opposes it due to projected $437 million premium increases and $187 million state fund costs. Sen. Laura Richardson advocates for a five-year pilot program to cover chronic weight management treatments, citing potential long-term savings from reduced healthcare costs.

Boehringer Ingelheim's obesity drug survodutide showed 13% weight loss in a Phase 3 trial, lower than Novo Nordisk's Wegovy and Eli Lilly's Zepbound. While the drug reduced liver fat by 63%, it appears less efficacious and tolerable compared to existing treatments.

New experimental weight-loss drugs are being developed to improve upon existing GLP-1 therapies like Zepbound and Wegovy. These therapies aim to offer better alternatives for patients experiencing nausea or daily pill regimens.